We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
It is expected that some of the selected projects will be able to reach patients before the end of the year and provide clinical assistance with new tools to combat SARS-CoV-2, as scientific evidence is obtained.
This afternoon the Consellera de Salut, Alba Vergés, has announced the projects that will receive funding from the emergency call promoted by the Catalonian Department of Health through the General Directorate of Research and Innovation in Health (DGRIS) with the collaboration of AQuAS and Biocat and addressed to the centers of the alliance IRISCAT (Institutes of Research and Innovation in Health of Catalonia). Two fo them from the Vall d'Hebron Research Institute (VHIR) which are led by doctors María José Buzón and Meritxell Genescà, and by Josep Quer and Andrés Antón, respectively;and one project from de Vall d'Hebron Institute of Oncology (VHIO) led by Dr. Joan Seoane.
In total, the DGRIS will finance a total of 19 research and innovation projects for the prevention and treatment of Covid-19 disease with 4 million euros. Projects to be funded include Covid-19 therapies (new therapies, antibody and plasma therapies, clinical trials with new combinations and uses of drugs already on the market, and clinical trials with investigational drugs for other indications); vaccines and preventive treatments; genetic studies and predictive studies (identification of virulence factors and prognostic biomarkers, and projects to study the population's immune response and prediction of complications).
Dr. Joan Seoane, Head of the VHIO Cancer Gene Expression Laboratory, co-director of the VHIO Pre-clinical and Translational Research program and professor ICREA leads a project to reposition an antibody against cancer as a potential treatment for cancer. Covid-19. Repositioning consists of seeking new therapeutic applications for an existing treatment, in this case, a therapeutic anti-LIF antibody, initially designed for cancer treatment, as an activator of the immune system of patients with Covid-19.
LIF is an immunosuppressive molecule that plays a crucial role in the implantation of the embryo in the maternal uterus, since it protects the embryo from the mother's immune system. Previous studies have shown that LIF is found at very high levels in some tumors, preventing the patient's immune system from destroying them. LIF has also been found to induce some tumor-associated viruses, and even other types of infections.
The project will identify whether SARS-CoV-2 is one of the viruses that LIF uses to prevent the immune system of patients from recognizing it. If so, LIF could be attacked with an antiviral drug blocking it, so the patient's immune system could detect the virus and attack it, thereby preventing infection.
Dr. Seoane's team has developed an antibody that attacks LIF in tumors (MSC1) in previous studies and is already in the clinical trial phase. Thus, if SARS-CoV-2 is confirmed to use LIF, it will be tested whether MSC1 is also effective against Covid-19.
Management, General Hospital
Neurology, General Hospital
Facilities and Technology Management, General Hospital
Communication, Corporate Strategy, and Citizen Services Department, Vall d'Hebron Barcelona Hospital Campus.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.